Search Result

Isoforms Recommended:	EZH2

Results for "

EZH2,

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Apoptosis (12) Autophagy (2) E1/E2/E3 Enzyme (1) Epigenetic Reader Domain (2) Fluorescent Dye (1) HDAC (1) HIF/HIF Prolyl-Hydroxylase (2) Histone Methyltransferase (76) HSP (1) Keap1-Nrf2 (1) Ligands for Target Protein for PROTAC (1) Orthopoxvirus (3) PARP (2) PROTAC Linkers (1) PROTACs (7) Sirtuin (1) Small Interfering RNA (siRNA) (3) Wnt (1)
By Research Areas:	Cancer (83) Cardiovascular Disease (1) Infection (3) Inflammation/Immunology (2)
Oligonucleotides:	Pre-designed siRNA Sets (3) siRNAs (3)

Inhibitors & Agonists

Fluorescent Dye

Biochemical Assay Reagents

Peptides

Natural
Products

Recombinant Proteins

Antibodies

Oligonucleotides

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-148458

EZH2-IN-14	Histone Methyltransferase	Cancer
EZH2-IN-14 is a selective *EZH2* (Histone Methyltransferase) inhibitor with an IC₅₀ of 12 nM. EZH2-IN-14 inhibits the methyltransferase activity of EZH2/PRC2 (that is, reducing H3K27me3). EZH2-IN-14 shows >200-fold selective for EZH2 over the highly homologous H3K27 methyltransferase EZH1 .

HY-147230

EZH2-IN-13	Histone Methyltransferase	Cancer
EZH2-IN-13 is a potent *EZH2* inhibitor, for details please refer to compound 73 in patent WO2017139404. EZH2-IN-13 can be used to study cancers or precancerous lesions associated with EZH2 activity .

HY-A0298

EZH2-IN-2	Histone Methyltransferase	Cancer
EZH2-IN-2 is a *EZH2* inhibitor extracted from patent WO2018133795A1, Compound Example 69, with an IC₅₀ of 64 nM. EZH2-IN-2 can be used for the research of cancer or precancerous condition related to EZH2 activity .

HY-RS04619

EZH2 Human Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
EZH2 Human Pre-designed siRNA Set A contains three designed siRNAs for EZH2 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

EZH2 Human Pre-designed siRNA Set A EZH2 Human Pre-designed siRNA Set A

HY-RS04620

Ezh2 Mouse Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
Ezh2 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Ezh2 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

Ezh2 Mouse Pre-designed siRNA Set A Ezh2 Mouse Pre-designed siRNA Set A

HY-RS04621

Ezh2 Rat Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
Ezh2 Rat Pre-designed siRNA Set A contains three designed siRNAs for Ezh2 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.

Ezh2 Rat Pre-designed siRNA Set A Ezh2 Rat Pre-designed siRNA Set A

HY-149463

EZH2-IN-16	Histone Methyltransferase	Cancer
EZH2-IN-16 (Compound 24) is an inhibitor for histone methyltransferase (EZH2). EZH2-IN-16 inhibits EZH2 and EZH2 Y641F, with IC₅₀ of 37.6 and 79.1 nM. EZH2-IN-16 inhibits proliferation of WSU-DLCL2, with GI₅₀ of 0.2 μM .

HY-139150

EZH2-IN-4	Histone Methyltransferase	Cancer
EZH2-IN-4 is an orally active, potent *EZH2* inhibitor with IC₅₀s of 0.923 nM and 2.65 nM against wild type (WT) 5-membered (5-mer) EZH2 and mutant 5-mer EZH2, respectively. EZH2-IN-4 has anti-cancer activity .

HY-141566

EZH2-IN-5	Histone Methyltransferase	Cancer
EZH2-IN-5 is a potent *EZH2* inhibitor with IC₅₀ values of 1.52 nM and 4.07 nM for wild-type and mutant Tyr641 EZH2, respectively .

HY-163741

EZH2-IN-19	Histone Methyltransferase	Cancer
EZH2-IN-19 (conpound N40) is a potent inhibitor of enhancer of zeste homolog 2 (EZH2) WT, with the IC₅₀ of 0.32 nM. EZH2-IN-19 plays an important role in cancer research .

HY-113786

EZH2-IN-21	Histone Methyltransferase	Cancer
EZH2-IN-21 is a potent inhibitor of the histone lysine methyltransferase enhancer of zeste homologue 2 (EZH2) with anticancer activity. EZH2-IN-21 is competitive with the cofactor SAM and noncompetitive with peptide or nucleosome substrates .

HY-122595

EZH2-IN-1	Histone Methyltransferase	Cancer
EZH2-IN-1 (compound 3) is a selective and SAM-competitive *EZH2* and *EZH1* inhibitor with an IC₅₀s of 32 nM, 197 nM and 213 nM for EZH2wt, EZH2 Y641N mutant and EZH1, respectively. EZH2-IN-1 reduces bulk H3K27me3 and H3K27me2 levels. EZH2-IN-1 has the potential for diffuse large B cell lymphoma research .

HY-161419

EZH2-IN-18	Histone Methyltransferase	Cancer
EZH2-IN-18 (compound 9e) is a potent inhibitor of enhancer of zeste homologue 2 (EZH2 ^WT) , with the IC₅₀ of 1.01 nM. EZH2-IN-18 shows inhibition in proliferation and induction in apoptosis in tumor cells .

HY-153191

EZH2-IN-15	Histone Methyltransferase	Cancer
EZH2-IN-15 is a *EZH2* inhibitor. EZH2-IN-15 has anti-tumor activity, and can be used for research of H3K27me3-dependent tumors .

HY-144096

EZH2-IN-11	Histone Methyltransferase	Cancer
EZH2-IN-11 is a potent inhibitor of *E2HZ. The oncogenic activities of EZH2* have been shown by a number of studies in various different cancer types. EZH2-IN-11 has the potential for the research of cancer diseases (extracted from patent WO2019204490A1, compound 17) .

HY-149726

EZH2-IN-17	Histone Methyltransferase	Cancer
EZH2-IN-17 (compound 28) is a potent and orally active *EZH2* inhibitor with an IC₅₀ value of 0.95 nM. EZH2-IN-17 exhibits high anti-proliferation activity against different lymphoma cell lines including WSU-DLCL2, Pfeiffer and Karpas-422 (IC50 values of 2.36 nM, 1.73 nM, and 1.82 nM, respectively) .

HY-163288

EZH2/HSP90-IN-29	Histone Methyltransferase HSP Apoptosis	Cancer
EZH2/HSP90-IN-29 is a dual inhibitor for *EZH2* and HSP90, with IC₅₀s of 6.29 nM and 60.1 nM, for EZH2 and HSP90, respectively. EZH2/HSP90-IN-29 increases apoptosis/necrosis-related gene expression, induces cell cycle arrest at M phase and inhibits reactive oxygen species (ROS) catabolism pathway. EZH2/HSP90-IN-29 is able to cross the blood-brain-barrier (BBB) .

HY-144094

EZH2-IN-9	Histone Methyltransferase	Cancer
EZH2-IN-9 is a potent inhibitor of *EZH2. EZH2* overexpression or mutations in the SET region (Y641F, Y641N, A687V, A677G point mutations) all lead to abnormal elevation of H3K27me3 and promote the growth and development of many types of tumors, such as breast cancer, prostate cancer, leukemia, etc. EZH2-IN-9 has the potential for the research of cancer diseases (extracted from patent WO2021180235A1, compound 17) .

HY-143616

EZH2-IN-7	Histone Methyltransferase	Cancer
EZH2-IN-7 is a potent inhibitor of *EZH2. EZH2* overexpression or mutations in the SET region (Y641F, Y641N, A687V, A677G point mutations) all lead to abnormal elevation of H3K27me3 and promote the growth and development of many types of tumors, such as breast cancer, prostate cancer, leukemia, etc. EZH2-IN-7 has the potential for the research of cancer diseases (extracted from patent WO2021129629A1, compound 259) .

HY-D2274

EZH2-AF647	Fluorescent Dye	Others
EZH2-AF647 is a fluorescent probe derived from UNC2239 that improves receptor TR-FRET properties by using Alexa 647 dye .

HY-147525

*PROTAC EZH2* Degrader-1** 1 Publications Verification	PROTACs Histone Methyltransferase	Cancer
PROTAC EZH2 Degrader-1 (Compound 150d), a potent PROTAC EZH2 Degrader, exerts inhibitory effect on EZH2 methyltransferase activity with the IC₅₀ of 2.7 nM. EZH2 plays an important role in many tumorigenesis and development processes .

HY-157164

*PROTAC EZH2* Degrader-2**	PROTACs Histone Methyltransferase	Cancer
PROTAC EZH2 Degrader-2 (compound E-3P-MDM2), an EZH2 inhibitor, is a PROTAC composed of Tazemetostat (EPZ6438) and an E3 ligase system ligand. PROTAC EZH2 Degrader-2 degrades EZH2 in SU-DHL-6 cells in a dose-dependent manner, inhibits the expression of H3K27me3, and simultaneously degrades EED and SUZ12 proteins without affecting their mRNA levels. PROTAC EZH2 Degrader-2 has anti-cancer and anti-proliferative activity .

HY-168131

*PROTAC EZH2* Degrader-3**	Histone Methyltransferase Apoptosis	Cancer
PROTAC EZH2 Degrader-3 (compound ZJ-20) is a *EZH2* degrader. PROTAC EZH2 Degrader-3 (5 μM, 24 h) not only potently inhibits the expression of EZH2 protein, but also had a strong inhibits effect on the expression levels of other subunits of PRC2 as well as H3k27me3 protein. PROTAC EZH2 Degrader-3 shows anti-proliferative activity and blocks the cell cycle in the G0-G1 phase and induces cell apoptosis((Blue: cereblon ligand Pomalidomide (HY-10984), Black: linker HY-W361751；Pink: EZH2 inhibitor Tazemetostat (HY-13803)) .

HY-P2266

SAH-EZH2	Histone Methyltransferase	Cancer
SAH-EZH2, a stable EZH2 α-helical peptide, is an EZH2/EED interaction inhibitor. SAH-EZH2 targets native embryonic ectoderm development (EED), disturbs its interactions with EZH1 and EZH2, and selectively decreases trimethylation of H3K27 .

HY-156292

*IHMT-EZH2-426*	Histone Methyltransferase	Cancer
IHMT-EZH2-426 (compound 38) is a potent and covalent *EZH2* degrader with IC₅₀s of 1.3 nM, 1.2 nM, and 1.7-3.5 nM against EZH2 wild-type, EZH2-A687V, and EZH2-Y641F/Y641N/Y641S, respectively. IHMT-EZH2-426 exhibits potent antiproliferation effects against both B-cell lymphoma and triple negative breast cancer (TNBC) cell lines by reducing the levels of H3K27me3 and EZH2 .

HY-161083

*PARP/EZH2-IN-2*	PARP Histone Methyltransferase	Cancer
PARP/EZH2-IN-2 (compound 12e) is a dual target PARP1 and *EZH2* inhibitor, with IC₅₀ values of 6.89 and 27.34 nM, respectively. PARP/EZH2-IN-2 shows anticancer activity, with no toxicity to normal cells. PARP/EZH2-IN-2 achieves synthetic lethality indirectly by inhibiting EZH2 to increase the sensitivity to PARP1, and induces cell death by regulating excessive autophagy .

HY-132885

*PARP/EZH2-IN-1*	PARP Histone Methyltransferase	Cancer
PARP/EZH2-IN-1 is a first-in-class dual PARP (IC₅₀ 6.87 nM) and *EZH2* (IC₅₀ 36.51 nM) inhibitor for triple-negative breast cancer with wild-type BRCA.

HY-15573

EI1 KB-145943	Histone Methyltransferase Apoptosis	Cancer
EI1 (KB-145943) is a potent and selective?EZH2?inhibitor with?IC₅₀?of 15 nM and 13 nM for EZH2 (WT) and EZH2 (Y641F), respectively.

HY-N5024

Gambogenic acid 1 Publications Verification	Histone Methyltransferase	Cancer
Gambogenic acid is an active ingredient that can be isolated from gamboge. Gambogenic acid acts as an effective inhibitor of *EZH2, specifically and covalently binds to Cys668 within the EZH2-SET domain, and induces EZH2* ubiquitination. Gambogenic acid can be used for the research of cancer ^[2].

HY-144330

TDI-6118	Histone Methyltransferase	Cancer
TDI-6118 (Compound 5) is a potent inhibitor of *EZH2. EZH2*-IN-12 has the potential for the research of central nervous system malignancies .

HY-148333

MS177 1 Publications Verification	PROTACs Histone Methyltransferase Apoptosis	Cancer
MS177 is an effective and fast-acting *EZH2* degrader. MS177 is a PROTAC that consists of a CRBN ligand, linker, and a potent enzymatic EZH2 inhibitor C24 (C24 IC₅₀): 12?nM). MS177 effectively depletes both canonical EZH2–PRC2 and noncanonical EZH2–cMyc complexes. MS177 induces leukaemia cell growth inhibition, apoptosis and cell cycle progression arrest .

HY-136188

UNC2399	Histone Methyltransferase	Cancer
UNC2399, a biotinylated UNC1999, is a selective *EZH2* inhibitor, maintaining high in vitro potency for EZH2, with an IC₅₀ of 17 nM ^[2].

HY-147091

Tazemetostat de(methyl morpholine)-COOH	Ligands for Target Protein for PROTAC	Cancer
Tazemetostat de(methyl morpholine)-COOH (compound 7) is a ligand for the PROTAC target protein *EZH2, which can be used to synthesis of EZH2* degraders (PROTACs). *EZH2* degraders have potent cell viability inhibition in diffuse large B-cell lymphoma (DLBCL) and other subtypes of lymphoma .

HY-101508

GNA002	Histone Methyltransferase	Cancer
GNA002 is a highly potent, specific and covalent *EZH2* (Enhancer of zeste homolog 2) inhibitor with an IC₅₀ of 1.1 μM. GNA002 can specifically and covalently bind to Cys668 within the EZH2-SET domain, triggering EZH2 degradation through COOH terminus of Hsp70-interacting protein (CHIP)-mediated ubiquitination. GNA002 efficiently reduces EZH2-mediated H3K27 trimethylation, reactivates polycomb repressor complex 2 (PRC2)-silenced tumor suppressor genes .

HY-145602

Tulmimetostat CPI-0209	Histone Methyltransferase	Cancer
Tulmimetostat (CPI-0209) is an orally active *EZH1/EZH2* inhibitor that targets and inhibits the *EZH2* enzyme.Tulmimetostat has antitumor activity and is used in a variety of solid tumor studies ^[2] .

HY-144882

(R)-HH2853	Histone Methyltransferase	Inflammation/Immunology Cancer
(R)-HH2853 is a mutant EZH2 inhibitor with an IC₅₀ of <100 nM for *EZH2-Y641F*. (R)-HH2853 can be used for cancer and autoimmune diseases (WO2018045971A1; compound 201) .

HY-154854

BBDDL2059	Histone Methyltransferase	Cancer
BBDDL2059 is a selective covalent inhibitor of histone methyltransferase EZH2 with an IC₅₀ of 1.5 nM for EZH2-Y641F. BBDDL2059 inhibits lymphoma cell growth at nanomolar concentrations and can be used for anticancer research .

HY-13803

Tazemetostat 55+ Cited Publications EPZ-6438; E-7438	Histone Methyltransferase Apoptosis	Cancer
Tazemetostat (EPZ-6438) is a potent, selective and orally available *EZH2* inhibitor. Tazemetostat inhibits the activity of human polycomb repressive complex 2 (PRC2)-containing wild-type EZH2 with a K_i value of 2.5 nM. Tazemetostat inhibits EZH2 with IC₅₀s of 11 and 16 nM in peptide assay and nucleosome assay, respectively. Tazemetostat inhibits rat EZH2 with an IC₅₀ of 4 nM. Tazemetostat also inhibits EZH1 with an IC₅₀ of 392 nM. Tazemetostat induces apoptosis and differentiation specifically in SMARCB1-deleted MRT cells .

HY-134899

CPI-1328	Histone Methyltransferase	Cancer
CPI-1328 is an *EZH2* inhibitor with a K_i value of 63 fM.

HY-101571A

PF-06821497	Epigenetic Reader Domain Histone Methyltransferase	Cancer
PF-06821497 (compound 23a) is a potent, selective and orally active Enhancer of Zeste Homolog 2 (EZH2) inhibitor, with a K_i value <0.1 nM against mutant Y641N EZH2. Exhibits robust tumor growth inhibition .

HY-148334

MS8815	PROTACs Histone Methyltransferase	Cancer
MS8815 is a selective enhancer of zeste homolog 2 (EZH2) PROTAC degrader. MS8815 has inhibition activity for EZH2 with an IC₅₀ value of 8.6 nM. MS8815 can be used for the research of triple-negative breast cancer (TNBC) .

HY-13803R

Tazemetostat (Standard)	Histone Methyltransferase Apoptosis	Cancer
Tazemetostat (Standard) is the analytical standard of Tazemetostat. This product is intended for research and analytical applications. Tazemetostat (EPZ-6438) is a potent, selective and orally available *EZH2* inhibitor. Tazemetostat inhibits the activity of human polycomb repressive complex 2 (PRC2)-containing wild-type EZH2 with a K_i value of 2.5 nM. Tazemetostat inhibits EZH2 with IC₅₀s of 11 and 16 nM in peptide assay and nucleosome assay, respectively. Tazemetostat inhibits rat EZH2 with an IC₅₀ of 4 nM. Tazemetostat also inhibits EZH1 with an IC₅₀ of 392 nM. Tazemetostat induces apoptosis and differentiation specifically in SMARCB1-deleted MRT cells .

HY-13500

GSK343 20+ Cited Publications	Histone Methyltransferase Autophagy	Cancer
GSK343 is a highly potent and selective *EZH2* inhibitor with an IC₅₀ of 4 nM.

HY-156615

Igermetostat	Histone Methyltransferase	Cancer
Igermetostat is EZH2 inhibitor, used in cancer research in vivo and in vitro .

HY-103682

PF-06726304 1 Publications Verification	Histone Methyltransferase	Cancer
PF-06726304 is a potent and selective *EZH2* inhibitor. PF-06726304 inhibits wild-type and Y641N mutant EZH2 with K_is of 0.7 and 3.0 nM, respectively. PF-06726304 displays robust antitumor growth activity .

HY-103682A

PF-06726304 acetate	Histone Methyltransferase	Cancer
PF-06726304 acetate is a potent and selective *EZH2* inhibitor. PF-06726304 acetate inhibits wild-type and Y641N mutant EZH2 with K_is of 0.7 and 3.0 nM, respectively. PF-06726304 acetate displays robust antitumor growth activity .

HY-111085

CPI-905	Histone Methyltransferase	Cancer
CPI-905 is a potent, selective, and cell-active *EZH2* inhibitor .

HY-117540

ZLD10A	Others	Cancer
ZLD10A is a highly potent and selective EZH2 inhibitor with the activity of inhibiting H3K27 methylation. ZLD10A can inhibit wild-type and mutant EZH2 with nanomolar potency and has more than 1000-fold selectivity for the other 10 histone methyltransferases. ZLD10A inhibited cell proliferation of DLBCL cell lines in a concentration- and time-dependent manner, showing a potential antiproliferative effect. ZLD10A can be used in the study of EZH2 mutant lymphomas .

HY-12856

GSK503 5+ Cited Publications	Histone Methyltransferase	Cancer
GSK503 is a potent and specific inhibitor of *EZH2* methyltransferase with K_i ^app values of 3 to 27 nM.

HY-133129

MS1943 1 Publications Verification	Histone Methyltransferase Apoptosis	Cancer
MS1943 is a first-in-class, orally bioavailable *EZH2* selective degrader, with an IC₅₀ of 120 nM. MS1943 significantly reduces EZH2 protein levels in numerous triple-negative breast cancer (TNBC) and other cancer and noncancerous cell lines. MS1943 effectively blocks proliferation of multiple TNBC and other cancer cell lines .

Cat. No.	Product Name	Type

HY-D2274

EZH2-AF647	Fluorescent Dyes/Probes
EZH2-AF647 is a fluorescent probe derived from UNC2239 that improves receptor TR-FRET properties by using Alexa 647 dye .

HY-12186G

3-Deazaneplanocin A hydrochloride (GMP) DZNep hydrochloride (GMP); NSC 617989 hydrochloride (GMP); 3-Deazaneplanocin hydrochloride (GMP)	Fluorescent Dye
3-Deazaneplanocin A (DZNep) hydrochloride (GMP) is 3-Deazaneplanocin A hydrochloride (HY-12186) produced by using GMP guidelines. GMP small molecules work appropriately as an auxiliary reagent for cell therapy manufacture. 3-Deazaneplanocin A hydrochloride is a potent histone methyltransferase EZH2 inhibitor ^[2].

Cat. No.	Product Name	Type

HY-12186G

3-Deazaneplanocin A hydrochloride (GMP) DZNep hydrochloride (GMP); NSC 617989 hydrochloride (GMP); 3-Deazaneplanocin hydrochloride (GMP)	Biochemical Assay Reagents
3-Deazaneplanocin A (DZNep) hydrochloride (GMP) is 3-Deazaneplanocin A hydrochloride (HY-12186) produced by using GMP guidelines. GMP small molecules work appropriately as an auxiliary reagent for cell therapy manufacture. 3-Deazaneplanocin A hydrochloride is a potent histone methyltransferase EZH2 inhibitor ^[2].

Cat. No.	Product Name	Target	Research Area

HY-P2266

SAH-EZH2	Histone Methyltransferase	Cancer
SAH-EZH2, a stable EZH2 α-helical peptide, is an EZH2/EED interaction inhibitor. SAH-EZH2 targets native embryonic ectoderm development (EED), disturbs its interactions with EZH1 and EZH2, and selectively decreases trimethylation of H3K27 .

Cat. No.	Compare	Product Name	Species	Source

HY-P702618

	EZH2 Protein, Human (P.pastoris, His) ENX-1; Enhancer of zeste homolog 2; Lysine N-methyltransferase 6	Human	P. pastoris
	The EZH2 protein is a member of the Polycomb group (PcG). EZH2 Protein, Human (P.pastoris, His) is the recombinant human-derived EZH2, expressed by P. pastoris , with C-6*His labeled tag. The total length of EZH2 Protein, Human (P.pastoris, His) is 746 a.a.,

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Species
Source
Tag
Accession
Gene ID
Molecular Weight
Purity
Endotoxin Level
Biological Activity
Appearance
Formulation
Storage & Stability
Shipping
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Cat. No.	Compare	Product Name	Application	Reactivity

HY-P80507

	*KMT6/EZH2* Antibody**	WB, ICC/IF, IHC-P	Human
	KMT6/EZH2 Antibody is a non-conjugated and Rabbit origined monoclonal antibody about 85 kDa, targeting to KMT6/EZH2. It can be used for WB,ICC/IF,IHC-P assays with tag free, in the background of Human.

HY-P83287

	KMT6 Antibody (YA3032) WVS; ENX1; KMT6; WVS2; ENX-1; EZH2b; KMT6A; EZH2	WB	Human
	KMT6 Antibody (YA3032) is a biotin-conjugated non-conjugated IgG antibody, targeting KMT6, with a predicted molecular weight of 85 kDa (observed band size: 98 kDa). KMT6 Antibody (YA3032) can be used for WB experiment in human background.